• $8.2M
    Market Cap
  • 2,209.52%
    1-Year Change
  • Drug Manufacturers - Specialty & Generic
    Industry
Annual
Quarterly
12/31/2020
Income Statement
Total Operating Revenue
735,690
N/A
Cost of Revenue
325,191
N/A
Gross Profit
410,499
N/A
Sales and Marketing Expense
120,637
N/A
Research and Development Expense
-321,332
N/A
Depreciation and Amortization Expense
232,542
N/A
Total Operating Expenses
4.8M
N/A
Operating Profit
-4.4M
N/A
Interest Income
N/A
N/A
Interest Expense
-1.5M
N/A
Interest Income and Expense and Net
-1.5M
N/A
Total Nonoperating Income and Expense
-1.9M
N/A
Income before Taxes
-6.3M
N/A
Income Taxes
N/A
N/A
Extraordinary Items
N/A
N/A
Net Income
-6.3M
N/A
Net Income from Continuing Operations Applicable to Common
-6.3M
N/A
Basic EPS and Net Income
-0.13
N/A
Diluted EPS and Net Income
-0.13
N/A
Basic Weighted Average Shares
49.2M
N/A
Diluted Weighted Average Shares
49.2M
N/A
Balance Sheet
Cash and Cash Equivalents
856,844
N/A
Short-Term Investments
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
856,844
N/A
Total Current Assets
2.3M
N/A
Accumulated Depreciation
-469,315
N/A
Property and Plant and Equipment and Net
1.6M
N/A
Total Long-Term Assets
301,604
N/A
Total Assets
11.0M
N/A
Income Taxes Payable
N/A
N/A
Total Short-Term Debt
1.8M
N/A
Total Current Liabilities
4.6M
N/A
Total Long-Term Debt
232,165
N/A
Total Long-Term Liabilities
2.2M
N/A
Total Liabilities
7.0M
N/A
Retained Earnings
-7.7M
N/A
Total Stockholders Equity
4.0M
N/A
Total Shares Outstanding
64.1M
N/A
Cash Flow
Cash from Operating Activities
-2.1M
N/A
Capital Expenditures
279,025
N/A
Cash from Investing Activities
-2.8M
N/A
Dividends Paid
N/A
N/A
Cash from Financing Activities
4.1M
N/A
Financials Ratio
Gross Margin
55.80%
N/A
Operating Margin
-600.20%
N/A
Return on Assets
-80.11%
N/A
Return on Equity
-171.48%
N/A
Revenue Growth
1,808.40%
N/A
Current Ratio
0.51
N/A
Cash Ratio
0.19
N/A
Debt-to-Equity Ratio
0.50
N/A
Debt-to-Assets Ratio
0.18
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow